Abstract Body

Background: CD4 mimic small compounds (CD4MCs), NBD-556 and its analogues, inhibit the gp120-CD4 interaction and can also induce conformational changes in the gp120 architecture thereby exposing masked epitopes of neutralizing antibodies on the Env protein. Recently, some groups have reported novel potent NBD analogues. We designed and synthesized five new NBD analogues (YIR compounds). In this study, we characterized CD4MC-resistant viruses induced by in vitro selection to these novel NBD analogues.

Methods: Resistant variants were induced by five CD4MCs (NBD-556, YYA-021, HAR1-71, JRC-II-191 or HAR-431) using the primary KP-5P virus (subtype B, R5) in PM1 cells. We constructed infectious KP-5P clones with CD4MC-resistant mutation following in vitro selection. The susceptibility of the infectious clones to the novel CD4MCs (YIR-327, YIR-329, YIR-438, YIR-501, YIR-504, DMJ-I-228 and DMJ-II-121) and other entry inhibitors (Maraviroc, Cenicriviroc, RPR103611 and IC9564) was tested in a TZM-bl assay.

Results: Resistance against five NBD analogues, NBD-556, YYA-021, HAR-171, JRC-II-191 and HAR-431, was associated with V255M, T375I, or M426I substitutions that line the Phe43 cavity of gp120. Two of three mutated residues, V255M and T375I, are located at the bottom of the Phe43 cavity, while M426I is at the edge of the cavity. Clones V255M or T375I were highly resistant against the five NBD analogues. These mutated clones were cross-resistant to all our novel CD4MCs, YIR-327, YIR-329, YIR-438, YIR-501 and YIR-504, and also to DMJ-I-228, DMJ-II-121. On the other hand, the clone with M426I was more resistant than those with V255M and T375I mutations to sCD4 but not as resistant to the CD4MCs tested, because the Phe43 residue of sCD4 is located at a shallow position in the cavity compared to the CD4MCs. However, the mutated clones retained wild type sensitivity to other entry inhibitors (Maraviroc, Cenicriviroc, RPR103611 and IC9564). These results suggest that two mutations at the bottom of Phe43 cavity are critically important not only for binding but also broad resistance to CD4MCs.

Conclusions: The mutations V255M and T375I at the bottom of Phe43 cavity can induce broad and potent cross-resistance to NBD analogues. These data provide additional knowledge for synthesizing novel NBD analogues with a high genetic barrier.